Publications
- Drug Resistance in Non-Hodgkin Lymphomas2020 | First Faculty of Medicine
- BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin Lymphomas2020 | First Faculty of Medicine
- Cotargeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma2019 | First Faculty of Medicine, Second Faculty of Medicine
- Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2-and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma2016 | First Faculty of Medicine, Second Faculty of Medicine
- Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells2015 | First Faculty of Medicine
- Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents2014 | First Faculty of Medicine
- In Vivo Growth of Mantle Cell Lymphoma Xenografts in Immunodeficient Mice Is Positively Regulated by VEGF and Associated with Significant Up-regulation of CD31/PECAM12013 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- The plant alkaloid and anti-leukemia drug homoharringtonine sensitizes resistant human colorectal carcinoma cells to TRAIL-induced apoptosis via multiple mechanisms2013 | Central Library of Charles University, First Faculty of Medicine
- Multi-level disruption of the extrinsic apoptotic pathway mediates resistance of leukemia cells to TNF-related apoptosis-inducing ligand (TRAIL)2013 | First Faculty of Medicine
- Resistance to TRAIL in mantle cell lymphoma cells is associated with the decreased expression of purine metabolism enzymes2013 | First Faculty of Medicine
Loading network view...